已收盤 02-06 16:00:00 美东时间
+0.590
+9.16%
Adicet Bio CEO to Present at Guggenheim Emerging Outlook Biotech Summit Adicet Bio, Inc., a clinical stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026.
01-30 20:00
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从9美元升至50美元;韦德布什:维持Ardelyx, Inc."跑赢大市"评级,目标价从16美元升至19美元
01-22 15:09
HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the price target from $9 to $50.
01-21 19:33
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and
01-07 20:14
Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.
01-07 02:42
Shares of Adicet Bio are trading lower after the clinical stage biotechnology company announced a one-for-16 reverse stock split.
2025-12-27 00:21
Adicet Bio shares are trading lower after the company announced a 1-for-16 reve...
2025-12-26 21:31
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
2025-11-10 17:17
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
2025-11-10 10:22
HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the price target from $4 to $9.
2025-11-07 20:38